While the dollar amount is small relative to market cap, the participation of the CEO and two other top executives in coordinated selling may signal reduced conviction at a leadership level. Traders should monitor for absence of offsetting buy signals and watch for any upcoming filings or guidance that could explain the timing.
VRTX drugs
VRTX drug pipeline →- ▲ povetacicept 6/10 Filed/PDUFA (BLA under FDA review for accelerated approval in IgAN); Phase 3 (RAINIER in IgAN); Phase 2b/3 (OLYMPUS in p · PDUFA date Nov 30, 2026
- ● inaxaplin 5/10 Phase 2/3
- ▲ ALYFTREK 4/10 Approved
- ● JOURNAVX 4/10 Approved
- ● TRIKAFTA 4/10 Approved
- 6 more · All VRTX drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Feb 25 $482.92entry
- T+1 · 9mo ago −0.58%α −0.03% · $480.12
- T+5 · 9mo ago −1.32%α −0.22% · $476.54
- T+20 · 8mo ago −5.79%α −0.55% · $454.96
- T+60 · 6mo ago −10.87%α −17.82% · $430.44
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Three senior executives at Vertex Pharmaceuticals, including the CEO and two EVPs, sold shares in a coordinated 7-day window, generating over $1.75 million in proceeds. All transactions were open-market sales at prevailing prices, with no grants, awards, or tax-related dispositions involved.
Key Financial Metrics
Key Facts
- CEO Reshma Kewalramani sold 400 shares for $191,900 in an open-market transaction.
- EVP Carmen Bozic sold 2,329 shares for $1.12M, the largest individual sale in the cluster.
- EVP Joy Liu sold 892 shares for $442,396, completing the cluster of C-suite dispositions.
- Total value of open-market sales: $1.753M across three insiders, all within seven days.
- Sales represent approximately 0.00145% of Vertex's $120.5B market cap, small in relative terms but notable due to concentration among top executives.
Financial Impact
$1.753 million in open-market share sales by C-suite executives
Risk Factors
- Perception of insider pessimism, especially given the rarity of CEO sales at this level.
- Potential for negative market reaction if no clear rationale (e.g., pre-arranged 10b5-1 plan) is disclosed.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (3 trades, 7d window) | cluster-VRTX-1772659472274 |
Track record
21 reports on VRTX
2 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +7.48% at T+20 after the Oct 16, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 2/10 Entry $537.79 Now $531.45 −1.18% settles Nov 24
- Nov 16, 20261d ago 144 Neutral 2/10 Entry $543.10 Now $531.45 −2.15% settles Nov 23
- Nov 16, 20261d ago 144 Neutral 1/10 Entry $544.98 Now $531.45 −2.48% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $542.00 Now $531.45 −1.95% settles Nov 23
- Nov 12, 20265d ago 144 Neutral 2/10 Entry $542.62 Now $531.45 −2.06% settles Nov 19
- Nov 6, 202611d ago 144 Neutral 2/10 Entry $547.09 to $538.60 Now $531.45 −2.86% ▼ −1.55% −4.15% vs SPY
- Nov 2, 202614d ago 8-K Bullish 6/10 Entry $530.76 to $547.89 Now $531.45 +0.13% ▲ +3.23% +3.81% vs SPY
- Oct 22, 202626d ago 3 Neutral 2/10 Entry $523.93 to $558.88 Now $531.45 +1.44% ▲ +6.67% +7.23% vs SPY
- Oct 20, 202628d ago 8-K Neutral 2/10 Entry $524.52 to $521.03 Now $531.45 +1.32% ▼ −0.67% −0.22% vs SPY
- Oct 16, 20264w ago Institutional Cluster Bullish 4/10 Entry $500.36 to $517.49 Now $531.45 +6.21% ▲ +3.42% +3.57% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers